Astrana signals at least mid-teens adjusted EBITDA growth into 2027 while forecasting 10%-15% Medicaid membership decline (NASDAQ:ASTH)
Astrana Health (ASTH) reported Q3 2026 revenue of $1.02B, up from prior periods, with adjusted EBITDA growth expected to reach mid-teens through 2027. CEO Brandon Sim cited growth, margin expansion, and execution. The company forecasts a 10%-15% decline in Medicaid membership.
How this was made
The 30-second read
Why it matters
The guidance sets a multi-year earnings trajectory while explicitly flagging Medicaid membership contraction, shaping near-term expectations for revenue mix and risk premium.
Market read
Traders can update models around ASTH’s 2027 EBITDA trajectory and Medicaid-driven revenue risk based on the stated guidance ranges.
What to watch
Investors may need more detail on reimbursement rates, churn/attrition dynamics, and cost inflation to judge whether EBITDA growth is resilient to Medicaid volume pressure.
Background
The piece summarizes Astrana Health’s Q3 2026 earnings call management commentary and forward-looking guidance.
Ticker impact
Astrana Health guided to at least mid-teens adjusted EBITDA growth into 2027 while forecasting a 10% to 15% Medicaid membership decline.
Likely modest support as investors weigh mid-teens EBITDA growth against Medicaid membership decline risk.
The article’s core new decision inputs are multi-year EBITDA growth guidance and a specific Medicaid membership decline forecast, both directly tied to ASTH’s earnings power and risk profile.
Market effects
Could reinforce investor focus on Medicaid membership trends as a key driver of managed-care earnings durability.
No clear regional spillover beyond US Medicaid managed care.
Limited, as the catalyst is US Medicaid membership and company-specific guidance.
Counterpoint
Mid-teens EBITDA growth may rely on margin expansion assumptions that could be harder to sustain if Medicaid membership declines faster than forecast.
Key entities
- companyAstrana Health
Guided to at least mid-teens adjusted EBITDA growth into 2027 and forecast a 10% to 15% Medicaid membership decline.




